RBGLY Deadline: Rosen Law Firm Urges Reckitt Benckiser Group PLC (OTC: RBGLY) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that Reckitt Benckiser Group PLC (OTC: RBGLY) Misled Investors Regarding its Business Operations.
According to the lawsuit, during the Class Period, defendants failed to warn investors and consumers: (1) that preterm infants were at an increased risk of developing necrotizing enterocolitis ('NEC') by consuming Reckitt's cow's milk-based formula, Enfamil; (2) of the attendant impact on Reckitt's sales of Enfamil and Reckitt's exposure to legal claims; and (3) as a result of the above, defendants' positive statements about Reckitt's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against Reckitt Benckiser Group PLC. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 4, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 hours ago
- Associated Press
Fortran Corporation Announces 2nd Quarter Earnings for 2025
HICKORY, N.C. - August 13, 2025 ( NEWMEDIAWIRE ) - Fortran Corporation (OTC: FRTN) Fortran Corporation (the 'Corporation ) is pleased to announce the 2nd quarter earnings of 2025. CEO & President Kent Greer stated, 'Our strong 2nd quarter performance demonstrates that our organization has forward and sustained momentum in the telecommunications business. With strong sales and AI becoming more of our core business, we will continue to move forward, setting new benchmarks within our operating companies.' About Fortran Corporation: Fortran Corporation is a telecommunication system integrator dedicated to designing, implementing and maintaining complex telecommunications solutions focused on cloud based and AI services. Fortran is comprised of engineering and design, network services, sales, remote monitoring, and on-site service. For more information, contact us at: [email protected]. Visit us at Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 Statements and information contained in this communication that refer to or include Fortran's estimated or anticipated future results or other non-historical expressions of fact are forward-looking statements that reflect Fortran's current perspective of existing trends and information as of the date of the communication. Forward looking statements generally will be accompanied by words such as 'anticipate,' 'believe,' 'plan,' 'could,' 'should,' 'estimate,' 'expect,' 'forecast,' 'outlook,' 'guidance,' 'intend,' 'may,' 'might,' 'will,' 'possible,' 'potential,' 'predict,' 'project,' or other similar words, phrases or expressions. Such forward-looking statements include but are not limited to. It is important to note that Fortran's plans, objectives, expectations and intentions are not predictions of actual performance. Actual results may differ materially from Fortran's current expectation depending upon a number of factors affecting Fortran's business. Factors that could cause or contribute to such differences include, but are not limited to, fluctuation in operating results, the ability of Fortran to compete successfully and other events. These factors also include, among others, the risks associated with the ongoing COVID-19 pandemic and related public health measures on its business, customers, markets and the worldwide economy: the inherent uncertainty associated with financial and other projections: the anticipated size of the markets and continued demand for Fortran's products: the impact of competitive products and pricing: changes in generally accepted accounting principles: successful compliance with governmental regulations applicable to Fortran's facilities, products and/or businesses; changes in laws, regulations and governmental policies: the loss of key senior management or staff: and other events factor and risks previously and from time to time disclosed in Fortran Corporation's filings with the OTC Markets Group Inc. including, specifically, those factors set forth in any 'Risk Factors' section contained in such filings. Kent Greer 828-324-4611 [email protected] View the original release on
Business Wire
2 hours ago
- Business Wire
Rosen Law Firm Encourages LifeMD, Inc. Investors to Inquire About Securities Class Action Investigation
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of LifeMD, Inc. (NASDAQ: LFMD) resulting from allegations that LifeMD may have issued materially misleading business information to the investing public. So What: If you purchased LifeMD securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On August 5, 2025, after the market closed, LifeMD reported its financial results for the second quarter of 2025. In this announcement, LifeMD announced revised guidance. Among other metrics, LifeMD stated that it was expecting total revenue in the range of $250 to $255 million, compared with previous guidance of $268 to $275 million. On this news, the price of LifeMD stock plummeted 44.8% on August 6, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Attorney Advertising. Prior results do not guarantee a similar outcome.
Associated Press
8 hours ago
- Associated Press
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - August 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the 'Class Period'). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 30, 2025. SO WHAT: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Novo Nordisk class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 30, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo Nordisk's growth potential. Notably, Novo Nordisk's asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood that such patients would switch to Novo Nordisk's branded alternatives. Further, defendants greatly overstated the potential GLP-1 market or otherwise, Novo's capability to penetrate said markets to achieve continued growth. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Novo Nordisk class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
